2006ǯ06·î17Æü

Ãæ¿õ¿À·ÐÇò·ìÉÂ(CNS-L)¤Ë¤Ä¤¤¤Æ Part02

¡¡Ãæ¿õ¿À·ÐÇò·ìÉÂ(CNS-L)¤Ë¤Ä¤¤¤Æµ­¤¹¡£
Ãæ¿õ¿À·ÐÇò·ìɤȤϡ¢Çò·ìɤ˹çÊ»¤¹¤ëÃæ¿õ¿À·Ð·Ï¾ã³²¤Î¼ç¤Ê¤â¤Î¤Ï¡¢½Ð·ì¤ÈÇò·ìɺÙ˦¤Î¿»½á¤Ë¸¶°ø¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡£¤³¤Î¤¦¤Á¡¢¿»½á¤¬µ¯¤³¤Ã¤¿¤¿¤á¤Ë¿»½á¤½¤Î¤â¤Î¡¢¤â¤·¤¯¤ÏǾ°µÐ¶¿Ê¤Ë¤è¤ê¿ºÌ¤Ê¿À·Ð¾É¾õ¤òÀ¸¤º¤ëÉÂÂÖ¤òÃæ¿õ¿À·ÐÇò·ìÉÂ(central nervous system leukemia)¡¢Çò·ìÉÂÀ­¿ñËì±ê¡¢¤Þ¤¿¤Ï¿ñËìÇò·ìɤȸƤ֡£°ÊÁ°¤Ï¼ç¤È¤·¤Æ¾®»ù¤ÎµÞÀ­¥ê¥ó¥ÑÀ­Çò·ìÉÂÎã¤Ë»¶È¯Åª¤Ë¸«¤é¤ì¤ë¤Ë²á¤®¤Ê¤«¤Ã¤¿¤¬¡¢³Æ¼ï¹³Çò·ìÉÂÌô¤Î³«È¯¤ä¿ºÞÊ»ÍÑÎÅË¡¤Ë¸«¤é¤ì¤ë¼£ÎÅË¡¤Î¿ÊÊâ¤Ë¤è¤ëÇò·ìÉ´µ¼Ô¤ÎÀ¸Â¸´ü´Ö¤Î±äŤËȼ¤¤¡¢¾®»ù¤Î¤ß¤Ê¤é¤ºÀ®¿Í¤Ë¤ª¤¤¤Æ¤âÃæ¿õ¿À·Ð¹çÊ»¾É¤Î¼çÂΤò¤Ê¤¹¤â¤Î¤È¤·¤ÆÃíÌܤµ¤ì¡¢¤½¤ÎͽËɵڤӼ£ÎŤνÅÍ×À­¤¬»ØÅ¦¤µ¤ì¤Æ¤¤¤ë¡£¸½ºß¡¢»ÈÍѤµ¤ì¤Æ¤¤¤ë¹³Çò·ìÉÂÌô¤ÎÂçÉôʬ¤ÏǾ·ì´É´ØÌç¤òÄ̲ᤷ¤Ë¤¯¤¤¤¿¤á¡¢Ä̾ï¤Î»ÈÍÑÎ̤ǤϿñ±ÕÃæ¤Ë½½Ê¬¤ÊÇ»ÅÙ¤¬ÆÀ¤é¤ì¤Ê¤¤¡£¤³¤Î¤¿¤á¡¢¥¯¥âËì¤Ë¿»½á¤·¤¿Çò·ìɺÙ˦¤ÏÁý¿£¤ò³¤±¿ñ±ÕÃæ¤ËÍ·½Ð¤¹¤ë¤è¤¦¤Ë¤Ê¤ê¡¢CNS-L¤È¤·¤ÆÎ×¾²Åª¤Ëǧ¼±¤µ¤ì¤ë¡£
¡¡ËܾɤϾ®»ù¤Ë¿¤¯¡¢ALL¤ÎÊý¤¬AML¤è¤ê¤â¿ôÇܵ¯¤³¤ê¤ä¤¹¤¤¤È¤µ¤ì¤Æ¤¤¤ë¡£¾É¾õ¤È¤·¤Æ¤Ï¡¢Â礭¤¯Ê¬¤±¤ë¤È¿À·ÐÁÈ¿¥¤ä¿ñËì¤Ø¤Î¿»½á¤Ëµ¯°ø¤¹¤ë¤â¤Î¤È¡¢¤³¤ì¤Ëȼ¤¦Ç¾°µÐ¶¿Ê¤Ë¤è¤ë¤â¤Î¤Î2¤Ä¤«¤éÀ®¤ë¡£¾É¾õ¤È¤·¤ÆºÇ¤â¿¤¤¤Î¤Ï¡¢Ç¾°µÐ¶¿Ê¤Ë¤è¤ë°­¿´¡¢ÓÒÅÇ(63%)¡¢Æ¬ÄË(61%)¡¢¤Ä¤¤¤ÇÓÏ̲(35%)¡¢Ê£»ë¡¢»ëÎϾ㳲¡¢¼Ð»ë¤Ê¤É¤Î´ã¾É¾õ(20%)¡¢Àº¿À¾É¾õ(20%)¡¢¤½¤Î¤Û¤«áÛÚ»¡¢ºª¿ç¡¢Èï»É·ãÀ­¤Îж¿Ê¡¢¸ÆµÛ¾ã³²¡¢Ä°ÎϾ㳲¤Ê¤É¤¬¤¢¤²¤é¤ì¤Æ¤¤¤ë¡£Î×¾²Ä§¸õ¤È¤·¤Æ¤Ï¡¢¹àÉô¹Åľ¡¢Kernigħ¸õ¤Î¤Û¤«¡¢¾®»ù¤Ç¤ÏË¥¹çÎ¥³«¤ò¤ß¤ë¤³¤È¤¬¤¢¤ë¡£Ç¾¿À·Ð·Ï¤Ç¤Ï¡¢´éÌÌ¿À·ÐËãáã¤ò¤­¤¿¤¹¤³¤È¤¬Â¿¤¯¡¢¤Ä¤¤¤ÇÂè­¶¡¢­¼¡¢­·Ç¾¿À·Ð¤Î½ç¤Ë¤ª¤«¤µ¤ì¤ë¤È¤µ¤ì¤Æ¤¤¤ë¡£ÉÂŪȿ¼Í¤äÆ·¹¦°Û¾ï¤ò¸«¤ë¤³¤È¤â¤¢¤ë¤¬¡¢Ëö¾¿¿À·ÐËãáã¤òÀ¸¤¸¤ë¤Î¤Ïµ©¤Ç¤¢¤ë¡£
¡¡CNS-L¤ÎÎ×¾²¿ÇÃǤηè¤á¼ê¤È¤Ê¤ë¤Î¤Ï¡¢¿ñ±Õ¤Î½ê¸«¤Ç¤¢¤ê¡¢¹øÄÇÀü»É¤ò¹Ô¤¦¡£·ë²Ì¡¢¿ñ±Õ°µ¤Î¾å¾º¤È¿ñ±ÕÃæ¤ÎºÙ˦¿ôÁý²Ã¤Ï80¡Á90%¾ÉÎã¤Ë¤ß¤é¤ì¡¢ºÙ˦³ØÅª¸¡ºº¤ò¹Ô¤¨¤Ð¡¢Çò·ìɺÙ˦¤Î¸ºß¤ò³Îǧ¤Ç¤­¤ë¡£¤µ¤é¤Ë¿ÇÃǤò³Î¼Â¤Ë¤¹¤ë¤Ë¤Ï¡¢¿ñ±ÕÇÝÍܤò¹Ô¤¤¡¢ºÙ¶Ý¡¢¿¿¶Ý¡¢¥¦¥£¥ë¥¹´¶À÷¤âÈÝÄꤷ¤Æ¤ª¤¯¤³¤È¤â½ÅÍפǤ¢¤ë¡£¤Þ¤¿¡¢Æ¬ÉôMRI,CT¤Ê¤É¤Ç¼ðáî·ÁÀ®¤òǧ¤á¤ë¤³¤È¤â¤Ç¤­¤ë¡£
¡¡°Ê¾å¤«¤é¡¢­¡Î×¾²¾É¾õ¡¢Ä§¸õ¡¡­¢¿ñ±Õ¸¡ºº¡¡­£Æ¬Éô²èÁü¿ÇÃÇ¡¡¤¬¿ÇÃǤǽÅÍפǤ¢¤ë¤È¹Í¤¨¤é¤ì¤ë¡£ËܾÉÎã¤Ç¤Ï¡¢Æ¬ÄË¡¢ÓÒµ¤¤Ê¤É¤ÎƬ³¸Æâ°µÐ¶¿Ê¤ò»×¤ï¤»¤ë¾É¾õ¡¢¿ñ±Õ¸¡ºº½ê¸«¤Ë¤ÆºÙ˦¿ôÁý¿(650/3)¤ÈºÙ˦¿Ç¾å¡¢Çò·ìɺÙ˦¤òǧ¤á¤¿¡£¤Þ¤¿¡¢Æ¬ÉôMRI¤Ë¤Æ¼ðáçºÙ˦¤Î¿ñËì¤Ø¤Î¿»½á¤È»×¤ï¤ì¤ë¾®Ç¾¤äÂçǾȾµå¤ÎǾɽ¡¢Ç¾¹Â¤ËÀþ¾ò¤Î¹â¿®¹æÎΰè¤òǧ¤á¤ë¡£¸Î¤Ë¡¢CNS-L¤È¤Î¿ÇÃǤ¬¤Ç¤­¤ë¤È»×¤ï¤ì¤ë¡£
¡¡TCCSG(Tokyo Children's Cancer Study Group)¤Î¿ÇÃÇ´ð½à¤Ë¤è¤ì¤Ð¡¢Ãæ¿õ¿À·Ð·Ï(CNS)¿»½á¤Î¿ÇÃÇ´ð½à¤Ï¡¢°Ê²¼¤ÎÄ̤ê¤Ç¤¢¤ë¡£
­¡²êµå¤Î̵ͭ¤ÏÁ´¤Æcytospin¤ò¹Ô¤¤¡¢Å¬ÀÚ¤ÊÀ÷¿§É¸ËܤòºîÀ½¤·¤Æ¸²Èù¶ÀŪ¤Ë·ÁÂÖ³ØÅª¿ÇÃǤò¹Ô¤Ã¤ÆÈ½Äꤹ¤ë¡£
­¢°Ê²¼¤ÎCNS status¤ÎʬÎà¤Ë´ð¤Å¤­¡¢CNS-1¤ÏCNS¿»½á±¢À­¡¢CNS-2,3¤ÏÃæ¿õ¿À·Ð¿»½áÍÛÀ­¤È¤¹¤ë¡£
¡¡CNS status¤ÎʬÎà
CNS-1¡§¿ñ±ÕÃæ¤Ë²êµå¤Ê¤·
CNS-2¡§WBC<5(=15/3)/¦Ìl¤«¤Ä²êµå¤¢¤ê
CNS-3¡§WBC>5(=15/3)/¦Ìl¤«¤Ä²êµå¤¢¤ê
­£WBC<5(=15/3)/¦Ìl¤Ç¤âCNS leukemia/lymphoma¤Î¾É¾õ¡¦Ä§¸õ(´éÌÌ¿À·ÐËãáã¡¢»ë¾²²¼Éô¾É¾õ¤Ê¤É)¤¬¤¢¤ë¤«¡¢¤¢¤ë¤¤¤ÏCT/MRI¤ÇCNSÉÂÊѤËÌ·½â¤·¤Ê¤¤½ê¸«¤òǧ¤á¤¿¾ì¹ç¤Ë¤âCNS¿»½áÍÛÀ­¤È¤·¡¢CNS-3¤ËʬÎह¤ë¡£

¡Ú´ØÏ¢µ­»ö¡Û
Ãæ¿õ¿À·ÐÇò·ìÉÂ(CNS-L)¤Ë¤Ä¤¤¤Æ Part01

Ãæ¿õ¿À·ÐÇò·ìÉÂ(CNS-L)¤Ë¤Ä¤¤¤Æ Part02

Ãæ¿õ¿À·ÐÇò·ìÉÂ(CNS-L)¤Ë¤Ä¤¤¤Æ Part03

¤Ë¤Û¤ó¥Ö¥í¥°Â¼ ɵ¤¥Ö¥í¥° °åÎÅŽ¥°å¼Ô¤Ø

¥È¥é¥Ã¥¯¥Ð¥Ã¥¯URL

¥³¥á¥ó¥È¤¹¤ë

̾Á°:
URL:
  ¾ðÊó¤òµ­²±¡§ ɾ²Á¡§  ´é   À±
 
 
 
¥Ö¥í¥°Æâ¸¡º÷
µ­»ö¤Þ¤È¤á°ìÍ÷











¥Ú¡¼¥¸¥é¥ó¥­¥ó¥°
¥Ö¥í¥°¥Ñ¡¼¥Ä
Archives
¤ªµ¤¤ËÆþ¤êÅÐÏ¿
Add to Google
My Yahoo!¤ËÄɲÃ
ËÜ¥µ¥¤¥È¤Ë¤Ä¤¤¤Æ
2006ǯ02·î27Æü¤è¤ê±¿±Ä¤·¤Æ¤¤¤ë°å³Ø·Ï¥Ë¥å¡¼¥¹¥µ¥¤¥È¤Ç¤¹¡£

Åö½é¤Ï¥ì¥Ý¡¼¥È¤Î·ÇºÜ¤ä°å»Õ¹ñ²È»î¸³¤ÎÌäÂê²òÀâ¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤·¤¿¤¬¡¢¤½¤Á¤é¤Ï¡Ø°å³ØÀ¸¤Î¥ì¥Ý¡¼¥È¤ä¤Ã¤Ä¤±¥µ¥¤¥È¡Ù¤Ë°Ü¹Ô¤·¤Æ¤ª¤ê¡¢¤³¤Á¤é¤Ï°å³Ø¥Ë¥å¡¼¥¹¤ò¼è¤ê°·¤¦¤³¤È¤È¤Ê¤ê¤Þ¤·¤¿¡£

¹ñÆâ¤Î3Âç¼ÀɤǤ¢¤ë´â¡¢Ç¾Â´Ãæ¡¢¿´¶Ú¹¼ºÉ¤«¤éµ©¤ÊÆñÉ¡¢ºÇ¿·¤Î¼£¸³¡¦¼£ÎÅË¡¤Ê¤É¡¢³Ø¤ó¤À¤³¤È¤òµ­¤·¤Æ¤¤¤­¤¿¤¤¤È»×¤¤¤Þ¤¹¡£»þ¤Ë¤ÏÈù¾Ð¤Þ¤·¤¤¥Ë¥å¡¼¥¹¤«¤é¡¢¼Ò²ñŪ¤Ê´Ø¿´»ö¤È¤Ê¤Ã¤Æ¤¤¤ë°å³Ø¤ÎÌäÂê¡¢´¶Æ°Åª¤ÊƮɵ­¤Ê¤É¡¢Éý¹­¤¯¼è¤ê°·¤Ã¤Æ¤¤¤­¤¿¤¤¤È»×¤¤¤Þ¤¹¡£

¸í¤ê¤Ê¤É¡¢¤´»ØÅ¦¤¬¤´¤¶¤¤¤Þ¤·¤¿¤é¥³¥á¥ó¥ÈÍó¤Ë¤ª´ê¤¤¤¤¤¿¤·¤Þ¤¹¡£ÊÖ»ö¤ÏÃÙ¤ì¤ë¤«¤âÃΤì¤Þ¤»¤ó¤¬¡¢¤Ç¤­¤ë¤«¤®¤êÂбþ¤·¤¿¤¤¤È»×¤¤¤Þ¤¹¡£¤Þ¤¿¥³¥á¥ó¥È¤Ë´Ø¤·¤Æ¤Ï¡¢ÊÖ»ö¤Ï¤·¤Æ¤¤¤Ê¤¯¤È¤â¡¢Á´¤ÆÆÉ¤Þ¤»¤Æ¤¤¤¿¤À¤¤¤Æ¤¤¤Þ¤¹¡£
livedoor Reader¤ËÅÐÏ¿
RSS
livedoor Blog¡Ê¥Ö¥í¥°¡Ë